In patients with type 2 diabetes, how does rosiglitazone (RGZ) compare with placebo or other drugs for cardiovascular (CV) outcomes?

Recent controversy over the CV safety of RGZ was sparked by the online publication of the meta-analysis by Nissen and Wolski, which received considerable attention in the lay press and led to a congressional hearing and calls to reform drug regulation. It also spurred Home et al to publish the interim analysis of the RECORD trial. Both studies have substantial limitations, so no simple answers are forthcoming.